Current Report Filing (8-k)
April 14 2022 - 4:06PM
Edgar (US Regulatory)
0001522767
false
0001522767
2022-04-14
2022-04-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of
The
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): April 14, 2022
MARIMED
INC. |
(Exact
name of registrant as specified in its charter) |
Delaware |
|
0-54433 |
|
27-4672745 |
(State
or other jurisdiction |
|
(Commission |
|
(IRS
Employer |
of
incorporation) |
|
File
Number) |
|
Identification
No.) |
10
Oceana Way, Norwood, Massachusetts |
|
02062 |
(Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (617) 795-5140
|
(Former
Name or Former Address, if Changed Since Last Report) |
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act: None.
Title
of each class |
|
Ticker
symbol(s) |
|
Name
of each exchange on which registered |
Not
Applicable. |
|
Not
Applicable. |
|
Not
Applicable. |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
8.01 Other Events.
On
April 14, 2022, MariMed Inc. (the “Company”) issued a press release, a copy of which is attached hereto as Exhibit 99.1 and
is incorporated herein by reference, announcing that the Maryland Medical Cannabis Commission has approved the transfer of 100% of the
ownership of Kind Therapeutics U.S.A., LLC, a leading vertically integrated cannabis business, to the Company.
Item 9.01. Financial Statements and Exhibits.
(d)
Exhibits
**********
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
MARIMED
INC. |
|
|
|
Dated:
April 14, 2022 |
|
|
|
By: |
/s/
Jon R. Levine |
|
|
Jon
R. Levine, Chief Financial Officer |
MariMed (QX) (USOTC:MRMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
MariMed (QX) (USOTC:MRMD)
Historical Stock Chart
From Apr 2023 to Apr 2024